Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml
暂无分享,去创建一个
A. Haese* | H. Lilja | M. Graefen | T. Steuber | H. Huland | J. Noldus | T. Piironen | K. Pettersson | T Piironen | K Pettersson | H Lilja | H Huland | C Becker | M Graefen | A Haese | T Steuber | J Noldus | C. Becker
[1] H. Lilja,et al. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. , 1999, Journal of andrology.
[2] A. Haese*,et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. , 2000, The Journal of urology.
[3] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[4] U Pichlmeier,et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. , 2001, The Journal of urology.
[5] T. Piironen,et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. , 2000, Urology.
[6] A W Partin,et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.
[7] R. Wolfert,et al. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. , 1998, Clinical chemistry.
[8] J. Oesterling,et al. The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.
[9] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[10] P. Riegman,et al. Characterization of the human kallikrein locus. , 1992, Genomics.
[11] T. Piironen,et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. , 1998, Urology.
[12] Eleftherios P. Diamandis,et al. The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.
[13] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[14] R. B. Smith,et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.
[15] R. Vessella,et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.
[16] P. Walsh. Radical prostatectomy, preservation of sexual function, cancer control. The controversy. , 1987, The Urologic clinics of North America.
[17] J. Oesterling,et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.
[18] T. Stamey,et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.
[19] R. Wolfert,et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. , 1998, Urology.
[20] D. Tindall,et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.
[21] D. Tindall,et al. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. , 1993, Biochemistry.
[22] D. Tindall,et al. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. , 1997, Urology.
[23] H. Lilja,et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.
[24] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[25] S. Katusic,et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. , 1999, The Journal of urology.
[26] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[27] B. Morris,et al. Primary structure of a human glandular kallikrein gene. , 1987, DNA.